



Heterocyclic Compounds as Anticancer Agents

Rafat M. Mohareb*

Department of Chemistry, Faculty of Science, Cairo University.

*Corresponding author: Rafat M. Mohareb
Department of Chemistry,
Faculty of Science,
Cairo University, A. R. Egypt.
E-mail: raafat_mohareb@yahoo.com

Received: December 26, 2013, Accepted: January 3, 2014, Published: January 7, 2014.

Cancer is a class of diseases in which a cell, or a group of cells display uncontrolled growth, invasion and sometimes metastasis.. These three malignant properties of cancers differentiate them from benign tumors, which are self-limited, and do not invade or metastasize. Most cancers form a tumor [1]. The branch of medicine concerned with the study, diagnosis, treatment, and prevention of cancer is oncology. In 2004, worldwide cancer caused 13% of all deaths. The leading causes were lung cancer, stomach cancer, colo-rectal cancer, liver cancer and breast cancer [2,3].

Cancers are primarily an environmental disease with 90-95% of cases due to lifestyle and environmental factors and 5-10% due to genetics. Common environmental factors leading to cancer death include: tobacco, diet, obesity, infections, radon exposure, radiation, stress, lack of physical activity and environmental pollutants [4]. These environmental factors cause abnormalities in the genetic material of cells [5].

Cancer affects people at all ages with the risk for most types increasing with age. The traditional anticancer drugs are the basis for the new drug development for cancer in which imidazole is an important moiety. Imidazole is a heterocyclic ring containing basically 3C and 2N atom present in 1st and 3rd positions [6]. The substitution on different positions gives a number of compounds of interest. It has been found that there are a variety of heterocyclic compounds were used as anticancer agents. Among the heterocyclic compounds the thiophene, pyridine, thiazole derivatives [7-12] showed high cytotoxicity towards the cancer cell lines. Structure activity relationship were reduced from biological results and will be used in further design of new active compound. Presently a number of drugs are used in the treatment of the cancer, but majority of them were produced controlled effect on the cancer cell. By application of these drugs the disease can be controlled.

The derivation of structure activity relationships (SARs) is central to molecular modelling. SARs are widely used in the

systematic design and refinement of pharmaceutical agents and in the identification of structural alerts of toxicity and mutagenicity. Because of their widespread importance both in fundamental and commercial research, many methodologies have been developed [13].

REFERENCES:

1. M. Filippova, W. Evans, R.Aragon, V. Filippov, V.M. Williams, L. Hong, M.E. Reeves, P.D. Hughes, The small splice variant of HPV16 E6, E6 α , reduces tumor formation in cervical carcinoma xenografts, *Virology* 450 (2014)153-164.
2. Ali, K. Fergus, F.C. Wright, K.I. Pritchard, A. Kiss, E. Warner, The impact of a breast cancer diagnosis in young women on their relationship with their mothers, *The Breast* 23(2014) 50-55.
3. S.W. Lam, C.R. Jimenez, E. Boven, Breast cancer classification by proteomic technologies: Current state of knowledge, *Cancer* 40 (2014) 129-138.
4. E. Deutsch, L. Maggiorella, P. Eschwege, J. Bourhis, J.C. Soria, B. Abdulkarim, Environmental, genetic, and molecular features of prostate cancer, *The Lancet Oncology* 5 (2004) 303-313.
5. M. J. Cubero, M. Saiz, L. J. Gonzalez, J.C. Alvarez, J.A. Lorente, J.M. Cozar, Genetic analysis of the principal genes related to prostate cancer: A review, *Urologic Oncology* 31 (2013) 1419-1429.
6. C.Y. Chan, L.S. New, H.K. Ho, E.C. Y. Chan, Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation, *Toxicology Letters* 206 (2011) 314-324.
7. M.S. Al-Said, M.S. Bashandy, S.I. Al-qasoumi, M.M. Ghorab, Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives, *Eur. J. Med. Chem.* 46 (2011) 137-141.

8. J.H. Park, M.I. El-Gamal, Y.S. Lee, C. H. Oh, New imidazo[2,1-b]thiazole derivatives: Synthesis, in vitro anticancer evaluation, and in silico studies, *Eur. J. Med. Chem.* 46 (2011) 5769-5777.
9. M. Banimustafa, A. Kheirollahi, M. Safavi, S.K. Ardestani, H. Aryapour, A. Foroumadi, S. Emami, Synthesis and biological evaluation of 3-(trimethoxyphenyl)-2(3H)-thiazole thiones as combretastatin analogs, *Eur. J. Med. Chem.* 70 (2013) 692-702.
10. K. Chavva, S. Pillalamarri, V. Banda, S. Gautham, J. Gaddamedi, P. Yedla, C.G. Kumar, N. Banda, Synthesis and biological evaluation of novel alkyl amide functionalized trifluoromethyl substituted pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents, *Bioorg. & Med. Chem. Lett.* 23 (2013) 5893-5895.
11. H. Liu, Y. Li, X.Y. Wang, B. Wang, H.Y. He, J.Y. Liu, M.L. Xiang, J. He, X.H. Wu, L. Yang, Synthesis, preliminary structure-activity relationships, and in vitro biological evaluation of 6-aryl-3-amino-thieno[2,3-b]pyridine derivatives as potential anti-inflammatory agents, *Bioorg. & Med. Chem. Lett.* 23 (2013) 2349-2352.
12. K. Chavva, S. Pillalamarri, V. Banda, S. Gautham, J. Gaddamedi, P. Yedla, C.G. Kumar, N. Banda, Synthesis and biological evaluation of novel alkyl amide functionalized trifluoromethyl substituted pyrazolo[3,4-b]pyridine derivatives as potential anticancer agents, *Bioorg. & Med. Chem. Lett.* 23 (2013) 5893-5895.
13. G. Fasano, A. Renga, M. D'Errico, 10- Formation geometries for multistatic SAR tomography, *Acta Astronautica*, 96 (2014) 11-22.

Rafat M. Mohareb was born in 1955, Professor of Pharmaceutical Organic Chemistry. Awarded the Fulbright fellowship, USA in 1999, Alexander von Humboldt fellowships, Germany, in 1987-1989. Published more than 160 scientific publications. Research interest including the Synthesis and SAR of newly synthesized heterocyclic compounds.